An interventional study of Awaken prone positioning ventilation in COVID-19, sponsored by Southeast University, China. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-09-05.
Sponsored by Southeast University, China · Not applicable, Interventional, and Treatment
Awaken prone positioning (APP) ventilation has been widely accepted as a standard regimen in the management of COVID-19 patients. Physiological studies have proved ventilation/perfusion improvement during APP in COVID-19, which was associated improved oxygenation. However, the optimal duration for APP was not yet demonstrated. In this study, we aimed at the prolonged APP to see whether this could improve patients outcomes.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 409 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Southeast University, China is the lead sponsor of 164 studies on the registry; 44 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Directive APP for a target of 12 hours per day or more
Procedure: Awaken prone positioning ventilation
No intervention on APP
patients were mandated to keep a prone position for at least 12 hours.
28-day intubation rate
whether the patients' were intubated
Time frame: follow-up till 28-day
APP duration/days
hours of APP per day
Time frame: follow-up till APP ended, daily duration of APP also recoreded, up to 7 days
Application of HFNC NIV vasopressor CRRT ECMO sedation, or complication
Whether to apply these treatments，any complications occur,days free from respiratory support and days free from invasive mechanical ventilation at 28 day
Time frame: follow-up till 28-day
mortality (ICU hospital) length of ICU (hospital) stay
mortality AND mortality and length of stay at 28 day
Time frame: follow-up during the ICU/hospital stay, up to 28 days
Adverse events of interest
All adverse events of interest that occur in both randomised arms will be reported up to day 28 post-randomisation, including the following: * Nausea, * Unintentional removal of intravenous access, * Pressure ulcer, * Unexpected respiratory cardiac arrest Nausea, Unintentional removal of intravenous access, Pressure ulcer，Unexpected respiratory cardiac arrest
Time frame: 28 post-randomisation
Plan to share: Yes — from the email：liulingdoctor@126.com
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Southeast University, China